MX2009011916A - Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne. - Google Patents

Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne.

Info

Publication number
MX2009011916A
MX2009011916A MX2009011916A MX2009011916A MX2009011916A MX 2009011916 A MX2009011916 A MX 2009011916A MX 2009011916 A MX2009011916 A MX 2009011916A MX 2009011916 A MX2009011916 A MX 2009011916A MX 2009011916 A MX2009011916 A MX 2009011916A
Authority
MX
Mexico
Prior art keywords
preparation
treatment
muscular dystrophy
compound
duchenne muscular
Prior art date
Application number
MX2009011916A
Other languages
English (en)
Spanish (es)
Inventor
Graham Michael Wynne
Stephen Paul Wren
Olivier De Moor
Alexander Charles Weymouth-Wilson
Robert Clarkson
Renate Van Well
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of MX2009011916A publication Critical patent/MX2009011916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2009011916A 2007-08-15 2008-08-14 Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne. MX2009011916A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy
PCT/EP2008/006719 WO2009021749A2 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
MX2009011916A true MX2009011916A (es) 2009-11-18

Family

ID=38566447

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009011916A MX2009011916A (es) 2007-08-15 2008-08-14 Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne.
MX2009011967A MX2009011967A (es) 2007-08-15 2008-08-14 Formas polimorficas de un compuesto para el tratamiento de la distrofia muscular de duchenne.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009011967A MX2009011967A (es) 2007-08-15 2008-08-14 Formas polimorficas de un compuesto para el tratamiento de la distrofia muscular de duchenne.

Country Status (17)

Country Link
US (2) US8138351B2 (enExample)
EP (2) EP2188270A2 (enExample)
JP (2) JP2010535830A (enExample)
KR (1) KR20100075777A (enExample)
CN (2) CN101896475A (enExample)
AR (1) AR068810A1 (enExample)
AU (2) AU2008286324A1 (enExample)
BR (2) BRPI0811315A2 (enExample)
CA (2) CA2685590A1 (enExample)
CL (1) CL2008002391A1 (enExample)
GB (1) GB0715937D0 (enExample)
IL (1) IL201908A0 (enExample)
MX (2) MX2009011916A (enExample)
PE (1) PE20090604A1 (enExample)
RU (1) RU2009141831A (enExample)
TW (1) TW200911767A (enExample)
WO (2) WO2009021748A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1986633T3 (pl) * 2006-02-10 2015-01-30 Summit Oxford Ltd Leczenie dystrofii mięśniowej Duchenne'a
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
MX2018012018A (es) * 2016-03-30 2019-07-04 Summit Oxford Ltd Composicion para el tratamiento de la distrofía muscular de duchenne.
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
US11622960B2 (en) 2017-06-19 2023-04-11 University Of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993659A (en) * 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH617809GA3 (enExample) * 1975-10-10 1980-06-30
US4110246A (en) * 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) * 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) * 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) * 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
DE3819051A1 (de) * 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
DE59206989D1 (de) * 1991-08-08 1996-10-02 Ciba Geigy Ag Farbstoffe, Verfahren zu deren Herstellung und deren Verwendung
DE59509233D1 (de) * 1994-02-24 2001-06-13 Haarmann & Reimer Gmbh Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren
US6004719A (en) * 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
JP3928070B2 (ja) * 1994-06-30 2007-06-13 スリーエム カンパニー 硬化指示性成形及びコーティング組成物
AU690302B2 (en) * 1994-06-30 1998-04-23 Dade Behring Inc. Bioactive porous partition members
US6222044B1 (en) * 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5645948A (en) * 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US6110638A (en) * 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US5914213A (en) * 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
US6177572B1 (en) * 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
US6312822B1 (en) * 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) * 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
FR2789582B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789581B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
EP1177194B1 (de) * 1999-05-07 2003-09-17 Basf Aktiengesellschaft 4-(3',4'-heterocyclylbenzoyl)pyrazole als herbizide
WO2000068210A1 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Benzohetero cyclylcyclo hexenone und ihre verwendung als herbizide
FR2794645B1 (fr) * 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
WO2001021583A1 (en) * 1999-09-24 2001-03-29 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
US6565987B2 (en) * 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
KR100825183B1 (ko) * 2000-11-30 2008-04-24 캐논 가부시끼가이샤 발광 소자 및 표시 장치
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP4481011B2 (ja) * 2002-03-05 2010-06-16 トランス テック ファーマ，インコーポレイテッド リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
AU2003261834A1 (en) * 2002-08-30 2004-05-04 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
US20040242673A1 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
AU2004270733B2 (en) * 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
EP1668417B1 (en) * 2003-09-22 2009-05-13 Agfa Graphics N.V. Photopolymerizable composition.
US7097888B2 (en) * 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2555313A1 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1794255B1 (en) * 2004-08-19 2016-11-16 LG Chem, Ltd. Organic light-emitting device comprising buffer layer and method for fabricating the same
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006099379A2 (en) * 2005-03-14 2006-09-21 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
JP2007086165A (ja) * 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
CA2630806C (en) * 2005-12-02 2015-01-06 Sachem, Inc. Anion-exchange displacement chromatography process and anionic organic compounds for use as displacer compounds in anion-exchange displacement chromatography process
KR101213485B1 (ko) * 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) * 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
PL1986633T3 (pl) * 2006-02-10 2015-01-30 Summit Oxford Ltd Leczenie dystrofii mięśniowej Duchenne'a
KR101325062B1 (ko) * 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자

Also Published As

Publication number Publication date
CL2008002391A1 (es) 2009-05-22
KR20100075777A (ko) 2010-07-05
WO2009021748A2 (en) 2009-02-19
RU2009141831A (ru) 2011-05-20
MX2009011967A (es) 2009-11-19
US20090048314A1 (en) 2009-02-19
US20100267961A1 (en) 2010-10-21
WO2009021748A3 (en) 2009-04-02
BRPI0811548A2 (pt) 2014-11-18
CA2685590A1 (en) 2009-02-19
IL201908A0 (en) 2010-06-16
EP2176246A2 (en) 2010-04-21
JP2010535829A (ja) 2010-11-25
AR068810A1 (es) 2009-12-09
CA2685939A1 (en) 2009-02-19
AU2008286324A1 (en) 2009-02-19
CN101679323A (zh) 2010-03-24
TW200911767A (en) 2009-03-16
WO2009021749A3 (en) 2009-04-02
JP2010535830A (ja) 2010-11-25
WO2009021749A8 (en) 2009-09-11
EP2188270A2 (en) 2010-05-26
CN101896475A (zh) 2010-11-24
WO2009021749A2 (en) 2009-02-19
US8138351B2 (en) 2012-03-20
AU2008286325A1 (en) 2009-02-19
BRPI0811315A2 (pt) 2015-01-27
GB0715937D0 (en) 2007-09-26
PE20090604A1 (es) 2009-05-16

Similar Documents

Publication Publication Date Title
MX2009011916A (es) Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne.
AU2009304508A8 (en) Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AP3643A (en) A novel non-aqueous topical solution of diclofenac and process for preparing the same
IL193315A (en) 5 - (Ethylsulfonyl) -2 - (Naphthalene-2-ram) benzo [d] oxazole and use in the treatment of muscular dystrophy or muscular dystrophy
AU2009290089A8 (en) Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
NZ602933A (en) Pyrrolobenzodiazepines used to treat proliferative diseases
EP2208166A4 (en) FAST ITERATIVE PROCESS FOR PROCESSING HAMILTON JACOBI EQUATIONS
EP2347018A4 (en) Process for production of direct reduced iron
WO2009032321A3 (en) A method for treating diabetes
SI2155563T1 (sl) Stroj z neposrednim pogonom za obdelavo vsebnikov
IL201308A0 (en) A new process for the manufacturing of the compound 2 - hydroxy - 3 - [5 - (morpholin - 4 - ylmethyl) pyridin - 2 - yl] 1h - indole - 5 - carbonitrile 701
UA105479C2 (uk) Спосіб одержання 2-сульфініл-1h-бензоімідазолів
EP2254898A4 (en) PROCESS FOR THE PRODUCTION OF ANHYDRO SUGAR ETHERS
GB2459808B (en) Benzothiazole and benzoxazole linked pyrrolo [2,1-C] [1,4] benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof
GB201208178D0 (en) Pharmaceutical composition for the treatment of duchenne muscular dystrophy
IL221341A0 (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
HK1136573A (en) Polymorphs of a compound for the treatment of duchenne muscular dystrophy
TWI348916B (en) A novel treatment tool for cancer: rna interference of bcas2
UA27333U (en) Process for the preparation of 6-alkylthio-5-benzoyl-3-ethoxycarbonyl-1-r-1,2-dihydropyridine-2-ones
UA36880U (ru) Способ получения соединения с потенциальными физиологическими свойствами n-ортометоксифенил-3-(n-метил-n-[2-морфолин-4-ил-оксоэтил]-амино)-сукцинимид
HK1180316A (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
HK1178890A (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
AU2008903080A0 (en) Brick lifting machine
HK1158207A (en) Process for the preparation of carbapenem compounds
HK1133007A (zh) 治療丙型肝炎的化合物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal